Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2020 Dec;8(23):1611.
doi: 10.21037/atm-20-2656.

Keynote-158 study, FDA granted accelerated approval of pembrolizumab for the treatment of patients with advanced PD-L1-positive cervical cancer

Edith Borcoman  1 , Christophe Le Tourneau  1   2   3
Affiliations
Editorial

Keynote-158 study, FDA granted accelerated approval of pembrolizumab for the treatment of patients with advanced PD-L1-positive cervical cancer

Edith Borcoman et al. Ann Transl Med. 2020 Dec.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: Both authors have completed the ICMJE uniform disclosure from (available at http://dx.doi.org/10.21037/atm-20-2656). Dr. Borcoman reports personal fees from MSD, outside the submitted work. Dr. Le Tourneau reports grants, personal fees and non-financial support from MSD, personal fees from BMS, personal fees from Merck Serono, personal fees from Roche, personal fees from Amgen, personal fees from Celgene, personal fees from Rakuten, personal fees from Seattle Genetics, personal fees from Novartis, personal fees from GSK, personal fees from Astra Zeneca, during the conduct of the study.

Comment on

References

    1. Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin 2015;65:87-108. 10.3322/caac.21262 - DOI - PubMed
    1. Chemoradiotherapy for Cervical Cancer Meta-Analysis Collaboration . Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: a systematic review and meta-analysis of individual patient data from 18 randomized trials. J Clin Oncol 2008;26:5802-12. 10.1200/JCO.2008.16.4368 - DOI - PMC - PubMed
    1. Pfaendler KS, Tewari KS. Changing paradigms in the systemic treatment of advanced cervical cancer. Am J Obstet Gynecol 2016;214:22-30. 10.1016/j.ajog.2015.07.022 - DOI - PMC - PubMed
    1. Moore DH, Blessing JA, McQuellon RP, et al. Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a gynecologic oncology group study. J Clin Oncol 2004;22:3113-9. 10.1200/JCO.2004.04.170 - DOI - PubMed
    1. Tewari KS, Sill MW, Long HJ, 3rd, et al. Improved survival with bevacizumab in advanced cervical cancer. N Engl J Med 2014;370:734-43. 10.1056/NEJMoa1309748 - DOI - PMC - PubMed